Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor- α production in human monocytes

Michael Heinzelmann, Marianne Miller, Andreas Platz, Laura E. Gordon, Daniel Herzig, Hiram C. Polk

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced monocyte activation. Summary Background Data: Heparin is widely used in clinical practice to inhibit the coagulation cascade. However, heparin also is a naturally occurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins. LPS is a component of gram-negative bacteria and is thought to be responsible for many of the deleterious effects seen in sepsis. The binding of LPS to CD14 induces a signaling cascade that results in the release of many inflammatory mediators, including tumor necrosis factor-alpha (TNF-α). Methods: Monocytes from healthy volunteers were isolated and cultured in the presence of saline, LPS (10 ng/ml), heparin (0.1 to 1000 μg/ml), or enoxaparin (0.1 to 1000 μg/ml). In blocking experiments, cells were pretreated for 60 minutes with the monoclonal anti-CD14 antibody MY4 (10 μg/ml) or with isotype-matched control IgG2 (10 μg/ml). TNF-α values were measured with enzyme-linked immunosorbent assay. Significance was assessed with analysis of variance. Results: Heparin (10 to 1000 μg/ml) and enoxaparin (1000 μg/ml) significantly enhanced LPS-induced TNF-α release. Heparin (1000 μg/ml) or enoxaparin (1000 μg/ml) did not produce TNF-α in the absence of LPS. Blockade of CD14 abrogated both LPS-induced TNF-α release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-α release. Conclusions: The effect of heparin to enhance LPS-induced TNF-α release is a biologic phenomenon that reveals a novel and potentially important host defense mechanism during endotoxemia and sepsis. Binding of LPS to CD14 is necessary to induce this phenomenon, suggesting that both heparin and enoxaparin induce signaling mechanisms that are downstream from the initial binding of LPS on CD14.

Original languageEnglish (US)
Pages (from-to)542-550
Number of pages9
JournalAnnals of Surgery
Volume229
Issue number4
DOIs
StatePublished - Apr 1999
Externally publishedYes

Fingerprint

Enoxaparin
Endotoxins
Lipopolysaccharides
Heparin
Monocytes
Tumor Necrosis Factor-alpha
Sepsis
Biological Phenomena
Endotoxemia
Low Molecular Weight Heparin
Immunologic Factors
Gram-Negative Bacteria
Anti-Idiotypic Antibodies
Analysis of Variance
Healthy Volunteers
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies

ASJC Scopus subject areas

  • Surgery

Cite this

Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor- α production in human monocytes. / Heinzelmann, Michael; Miller, Marianne; Platz, Andreas; Gordon, Laura E.; Herzig, Daniel; Polk, Hiram C.

In: Annals of Surgery, Vol. 229, No. 4, 04.1999, p. 542-550.

Research output: Contribution to journalArticle

Heinzelmann, Michael ; Miller, Marianne ; Platz, Andreas ; Gordon, Laura E. ; Herzig, Daniel ; Polk, Hiram C. / Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor- α production in human monocytes. In: Annals of Surgery. 1999 ; Vol. 229, No. 4. pp. 542-550.
@article{458bc452e54a4d6f906440eaaffdc067,
title = "Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor- α production in human monocytes",
abstract = "Objective: To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced monocyte activation. Summary Background Data: Heparin is widely used in clinical practice to inhibit the coagulation cascade. However, heparin also is a naturally occurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins. LPS is a component of gram-negative bacteria and is thought to be responsible for many of the deleterious effects seen in sepsis. The binding of LPS to CD14 induces a signaling cascade that results in the release of many inflammatory mediators, including tumor necrosis factor-alpha (TNF-α). Methods: Monocytes from healthy volunteers were isolated and cultured in the presence of saline, LPS (10 ng/ml), heparin (0.1 to 1000 μg/ml), or enoxaparin (0.1 to 1000 μg/ml). In blocking experiments, cells were pretreated for 60 minutes with the monoclonal anti-CD14 antibody MY4 (10 μg/ml) or with isotype-matched control IgG2 (10 μg/ml). TNF-α values were measured with enzyme-linked immunosorbent assay. Significance was assessed with analysis of variance. Results: Heparin (10 to 1000 μg/ml) and enoxaparin (1000 μg/ml) significantly enhanced LPS-induced TNF-α release. Heparin (1000 μg/ml) or enoxaparin (1000 μg/ml) did not produce TNF-α in the absence of LPS. Blockade of CD14 abrogated both LPS-induced TNF-α release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-α release. Conclusions: The effect of heparin to enhance LPS-induced TNF-α release is a biologic phenomenon that reveals a novel and potentially important host defense mechanism during endotoxemia and sepsis. Binding of LPS to CD14 is necessary to induce this phenomenon, suggesting that both heparin and enoxaparin induce signaling mechanisms that are downstream from the initial binding of LPS on CD14.",
author = "Michael Heinzelmann and Marianne Miller and Andreas Platz and Gordon, {Laura E.} and Daniel Herzig and Polk, {Hiram C.}",
year = "1999",
month = "4",
doi = "10.1097/00000658-199904000-00014",
language = "English (US)",
volume = "229",
pages = "542--550",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor- α production in human monocytes

AU - Heinzelmann, Michael

AU - Miller, Marianne

AU - Platz, Andreas

AU - Gordon, Laura E.

AU - Herzig, Daniel

AU - Polk, Hiram C.

PY - 1999/4

Y1 - 1999/4

N2 - Objective: To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced monocyte activation. Summary Background Data: Heparin is widely used in clinical practice to inhibit the coagulation cascade. However, heparin also is a naturally occurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins. LPS is a component of gram-negative bacteria and is thought to be responsible for many of the deleterious effects seen in sepsis. The binding of LPS to CD14 induces a signaling cascade that results in the release of many inflammatory mediators, including tumor necrosis factor-alpha (TNF-α). Methods: Monocytes from healthy volunteers were isolated and cultured in the presence of saline, LPS (10 ng/ml), heparin (0.1 to 1000 μg/ml), or enoxaparin (0.1 to 1000 μg/ml). In blocking experiments, cells were pretreated for 60 minutes with the monoclonal anti-CD14 antibody MY4 (10 μg/ml) or with isotype-matched control IgG2 (10 μg/ml). TNF-α values were measured with enzyme-linked immunosorbent assay. Significance was assessed with analysis of variance. Results: Heparin (10 to 1000 μg/ml) and enoxaparin (1000 μg/ml) significantly enhanced LPS-induced TNF-α release. Heparin (1000 μg/ml) or enoxaparin (1000 μg/ml) did not produce TNF-α in the absence of LPS. Blockade of CD14 abrogated both LPS-induced TNF-α release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-α release. Conclusions: The effect of heparin to enhance LPS-induced TNF-α release is a biologic phenomenon that reveals a novel and potentially important host defense mechanism during endotoxemia and sepsis. Binding of LPS to CD14 is necessary to induce this phenomenon, suggesting that both heparin and enoxaparin induce signaling mechanisms that are downstream from the initial binding of LPS on CD14.

AB - Objective: To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced monocyte activation. Summary Background Data: Heparin is widely used in clinical practice to inhibit the coagulation cascade. However, heparin also is a naturally occurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins. LPS is a component of gram-negative bacteria and is thought to be responsible for many of the deleterious effects seen in sepsis. The binding of LPS to CD14 induces a signaling cascade that results in the release of many inflammatory mediators, including tumor necrosis factor-alpha (TNF-α). Methods: Monocytes from healthy volunteers were isolated and cultured in the presence of saline, LPS (10 ng/ml), heparin (0.1 to 1000 μg/ml), or enoxaparin (0.1 to 1000 μg/ml). In blocking experiments, cells were pretreated for 60 minutes with the monoclonal anti-CD14 antibody MY4 (10 μg/ml) or with isotype-matched control IgG2 (10 μg/ml). TNF-α values were measured with enzyme-linked immunosorbent assay. Significance was assessed with analysis of variance. Results: Heparin (10 to 1000 μg/ml) and enoxaparin (1000 μg/ml) significantly enhanced LPS-induced TNF-α release. Heparin (1000 μg/ml) or enoxaparin (1000 μg/ml) did not produce TNF-α in the absence of LPS. Blockade of CD14 abrogated both LPS-induced TNF-α release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-α release. Conclusions: The effect of heparin to enhance LPS-induced TNF-α release is a biologic phenomenon that reveals a novel and potentially important host defense mechanism during endotoxemia and sepsis. Binding of LPS to CD14 is necessary to induce this phenomenon, suggesting that both heparin and enoxaparin induce signaling mechanisms that are downstream from the initial binding of LPS on CD14.

UR - http://www.scopus.com/inward/record.url?scp=0033510921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033510921&partnerID=8YFLogxK

U2 - 10.1097/00000658-199904000-00014

DO - 10.1097/00000658-199904000-00014

M3 - Article

C2 - 10203088

AN - SCOPUS:0033510921

VL - 229

SP - 542

EP - 550

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -